Skip to main content

PLUS THERAPEUTICS INC

For the period ended Mar 31, 2024. Filed May 15, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Stockholders’ Equity/(Deficit

(In thousands, except share data)

Convertible · Additional · Total
Preferred stock · preferred stock · Common stock · Treasury Stock · paid-in · Accumulated · stockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · (deficit)/equity
Balance at December 31, 2022—$—1,952$—2,240,092$2—$—$473,628$(467,185)$6,445
Stock-based compensation————————140—140
Sale of common stock, net————168,164———895—895
Issuance of Series F preferred stock1———————1—1
Net loss—————————(4,805)(4,805)
Balance at March 31, 20231$—1,952$—2,408,256$2—$—$474,664$(471,990)$2,676
Balance at December 31, 2023—$—1,952$—4,522,656$5(78,559)$(126)$479,274$(480,501)$(1,348)
Stock-based compensation————————146—146
Purchase of treasury stock——————(179,866)(374)——(374)
Net loss—————————(3,261)(3,261)
Balance at March 31, 2024—$—1,952$—4,522,656$5(258,425)$(500)$479,420$(483,762)$(4,837)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.